for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AngioDynamics, Inc.

ANGO.OQ

Latest Trade

15.28USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

13.77

 - 

25.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.28
Open
--
Volume
--
3M AVG Volume
6.41
Today's High
--
Today's Low
--
52 Week High
25.45
52 Week Low
13.77
Shares Out (MIL)
37.62
Market Cap (MIL)
576.34
Forward P/E
130.38
Dividend (Yield %)
--

Next Event

Q2 2020 AngioDynamics Inc Earnings Release

Latest Developments

More

Angiodynamics Says CFO Michael Greiner Will Be Departing Co

Angiodynamics Q1 Adjusted Earnings Per Share $0.08

Angiodynamics Acquires Eximo Medical, Ltd. And Its Innovative 355Nm Laser Atherectomy Technology

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AngioDynamics, Inc.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Vascular Interventions & Therapies, Vascular Access and Oncology. The Company's Vascular Interventions & Therapies products include Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines. Through its subsidiary, Eximo Medical, Ltd., the Company operates 355 nanometers (nm) wavelength laser-technology platform.

Industry

Medical Equipment & Supplies

Contact Info

14 Plaza Dr

+1.518.7981215

http://www.angiodynamics.com/

Executive Leadership

Howard W. Donnelly

Independent Chairman of the Board

James C. Clemmer

President, Chief Executive Officer, Director

Stephen A. Trowbridge

Interim Chief Financial Officer, Senior Vice President, General Counsel

Brent J. Boucher

Senior Vice President and General Manager, Oncology/Surgery

Chad T. Campbell

Senior Vice President and General Manager, Vascular Access

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.3K

2019

0.4K

2020(E)

0.3K
EPS (USD)

2017

0.730

2018

0.740

2019

0.830

2020(E)

0.118
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.29
Price To Book (MRQ)
0.95
Price To Cash Flow (TTM)
42.58
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-1.85
Return on Equity (TTM)
-1.73

Latest News

Latest News

AngioDynamics to pay $12.5 million over false claims allegations: U.S. Justice Department

AngioDynamics Inc has agreed to pay the U.S. government $12.5 million to resolve allegations it caused healthcare providers to submit false claims to federal healthcare programs over the use of two medical devices, the Justice Department said on Wednesday.

BRIEF-AngioDynamics Q3 Earnings Per Share $0.37

* ANGIODYNAMICS REPORTS FISCAL 2018 THIRD QUARTER FINANCIAL RESULTS

BRIEF-Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic Cancer

* ANGIODYNAMICS RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE NANOKNIFE® SYSTEM FOR THE TREATMENT OF STAGE III PANCREATIC CANCER

BRIEF-AngioDynamics Says U.S. Tax Reform To Have Impact Of $0.02- $0.04 On Non-GAAP Adjusted EPS In FY 2018

* ANGIODYNAMICS SAYS U.S. TAX REFORM ACT TO HAVE AN IMPACT IN RANGE OF $0.02- $0.04 ON NON-GAAP ADJUSTED EPS IN FY 2018 -SEC FILING Source: (http://bit.ly/2mfAFmM) Further company coverage:

BRIEF-AngioDynamics Q2 GAAP Earnings Per Share $0.01

* ANGIODYNAMICS REPORTS FISCAL 2018 SECOND QUARTER FINANCIAL RESULTS

BRIEF-AngioDynamics reports fiscal 2018 first quarter results

* Q1 adjusted non-GAAP earnings per share $0.12 excluding items

BRIEF-AngioDynamics reports Q4 loss per share $0.30

* Reports FY 2017 GAAP EPS of $0.19; adjusted EPS of $0.73, up 22% compared to FY2016

BRIEF-AngioDynamics announces FDA clearance for Solero microwave tissue ablation system

* AngioDynamics announces FDA clearance for the solero microwave tissue ablation system

BRIEF-AngioDynamics lawsuit claims C.R. Bard is violating antitrust laws, harming competition, limiting access

* AngioDynamics - "C.R. Bard has illegally tied sale of tip location systems to line of peripherally inserted central catheters," as per lawsuit filed by co

BRIEF-Angiodynamics announces pricing of secondary offering by selling stockholders

* Angiodynamics announces pricing of secondary offering by selling stockholders

BRIEF-Angiodynamics reports Q3 earnings per share $0.08

* Q3 earnings per share view $0.15 -- Thomson Reuters I/B/E/S

BRIEF-Angiodynamics receives CE mark certification for the Solero Microwave Tissue Ablation System

* Angiodynamics receives CE mark certification for the Solero Microwave Tissue Ablation System Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up